Evidence map›Paper›PMID 39381021›Full record

ArticleThe Lancet regional health. Western Pacific2024

Ear disease, hearing loss, and cognitive outcomes in high school children who were previous participants in a randomized placebo controlled trial of an 11 valent conjugate pneumococcal vaccine administered in infancy.

Andrea S Miele, Elisabeth D Root, Phyllis Carosone-Link, Veronica Tallo, Marilla Lucero, Diozele Hazel Sanvictores, Yun Ye, Kenny H Chan, Eric A F Simões

Abstract read
In one paragraph

Article in The Lancet regional health. Western Pacific, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrea S MieleDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
Elisabeth D RootInstitute for Disease Modeling, Bill & Melinda Gates Foundation, Seattle, WA, USA.
Phyllis Carosone-LinkDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
Veronica TalloDepartment of Clinical Trials, Epidemiology and Biostatistics, Research Institute for Tropical Medicine Department of Health, Muntinlupa, Manila, Philippines.
Marilla LuceroDepartment of Clinical Trials, Epidemiology and Biostatistics, Research Institute for Tropical Medicine Department of Health, Muntinlupa, Manila, Philippines.
Diozele Hazel SanvictoresDepartment of Clinical Trials, Epidemiology and Biostatistics, Research Institute for Tropical Medicine Department of Health, Muntinlupa, Manila, Philippines.
Yun YeDivision of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, USA.
Kenny H ChanDepartment of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
Eric A F SimõesDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The WHO estimates that close to 1.7 billion people worldwide have hearing loss; 34 million of whom are children, with 90% residing in low- and middle-income countries. While the effects of ear disease and hearing loss on language, academic, and behavioral development are established, there is remarkably little data on intellectual and other cognitive differences. Methods: Here we report results from an extension of a randomized controlled vaccination trial originally carried out between 2000 and 2004. Primary caregivers completed demographic and household questionnaires. Beginning in 2016, children were followed up for a hearing and ear disease evaluation. Participants also completed extensive cognitive testing, which included the domains of IQ, language, attention and processing speed, visual and visuospatial skills, and learning and memory. The association between ear disease and hearing loss and each of the cognitive outcomes was examined using multivariate linear regression models. Findings: We followed up 8926 children ages 14-19 years old. Children with hearing loss or ear disease had lower socioeconomic status compared to children without. However, even after controlling for a high number of covariates, all levels of ear disease or hearing loss were associated with clinically relevant reductions across all cognitive domains, though effect sizes were small. Even mild ear disease or hearing loss was associated with a -0.15 (95% CI: -0.20, -0.11) and a -0.23 (95% CI: -0.32, -0.14) standard deviation reduction, respectively, in IQ. The effects of ear disease and hearing loss were additive as children with both had the lowest cognitive scores. Interpretation: Untreated ear disease and hearing loss exert measurable effects on cognition that are able to be detected into the teenage years. Early identification of hearing loss and chronic ear disease may have lifelong benefits. Individuals with ear disease and/or hearing loss may require supports and services in addition to those related to speech and language therapy. Funding: The Bill and Melinda Gates Foundation OPP1142570.

Indexed as

Adolescent healthEpidemiologyNeuropsychologyPhilippinesSchool success

Identifiers

PMID39381021
PMCPMC11459003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.